T 2080/13 (Bone mineralisation/UCB PHARMA) of 8.9.2017

European Case Law Identifier: ECLI:EP:BA:2017:T208013.20170908
Date of decision: 08 September 2017
Case number: T 2080/13
Application number: 06011535.9
IPC class: C12N 15/12
Language of proceedings: EN
Distribution: D
Download and more information:
Decision text in EN (PDF, 231 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: Compositions and methods for increasing bone mineralisation
Applicant name: UCB Pharma S.A.
Opponent name: Mereo Biopharma 3 Limited
Eli Lilly and Company
Board: 3.3.08
Headnote: -
Relevant legal provisions:
European Patent Convention Art 113(2)
Keywords: Basis of decision - revocation of the patent at request of the patent proprietor


Cited decisions:
T 0073/84
Citing decisions:
T 0564/17
T 1659/18

Summary of Facts and Submissions

I. The patent proprietor (appellant I), opponent 1 (appellant II) and opponent 2 (appellant III) filed an appeal against the interlocutory decision of an opposition division dated 2 August 2013, whereby European patent No. 1721979 was maintained in amended form.

II. With its statement of grounds of appeal, appellant I filed nine new sets of claims as its main request and auxiliary requests 1 to 8. Later on, auxiliary requests 1 to 8 were replaced by auxiliary requests 1 to 20.

III. Appellants II and III requested that the decision under appeal be set aside and the patent revoked.

IV. The parties were summoned to oral proceedings to be held on 6 October 2017. In a communication pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal (RPBA) annexed to the summons, the board informed the parties of its provisional, non-binding opinion on some of the issues of the appeal proceedings.

V. By letter dated 5 September 2017, appellant I informed the board that it no longer approved the text of the patent as granted or as amended by way of any of the claim requests on file. Appellant I also stated that it would not be filing any further claim requests and requested revocation of the patent in accordance with Article 113(2) EPC.

VI. Oral proceedings were cancelled.

Reasons for the Decision

1. According to Article 113(2) EPC, the European Patent Office may decide upon the European patent only in the text submitted to it, or agreed, by the proprietor of the patent.

2. Agreement cannot be held to be given if the patent proprietor expressly states that it no longer approves the text of the patent as granted or as amended by way of any of the claim requests on file and that it will not be filing any further claim requests (cf. point V above).

3. There is therefore no text of the patent on the basis of which the board can consider the appeal. It is established case law that in these circumstances, the proceedings are to be terminated by a decision ordering revocation of the patent, without going into the substantive issues (see decision T 73/84, OJ EPO, 1985, 241 and Case Law of the Boards of Appeal of the EPO, 8th edition, 2016, IV.C.5.2, page 979).


For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.

Quick Navigation